{"gene":"LMO2","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1997,"finding":"LMO2 acts as a bridging molecule in erythroid cells, forming a pentameric DNA-binding complex with TAL1, E47 (E2A), GATA-1, and LDB1/NLI that binds a bipartite DNA motif comprising an E-box (CAGGTG) followed ~9 bp downstream by a GATA site; in vivo assembly requires all five proteins and the complex functions as a transcriptional transactivator.","method":"Co-immunoprecipitation, gel-shift/EMSA (CASTing), mammalian two-hybrid, reporter transactivation assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (Co-IP, EMSA, two-hybrid, reporter assay) in a single rigorous study establishing both the complex composition and DNA-binding specificity; replicated by companion papers","pmids":["9214632"],"is_preprint":false},{"year":1994,"finding":"LMO2 (RBTN2) is a nuclear protein expressed in the erythroid lineage; homozygous knockout in mice causes complete failure of yolk sac erythropoiesis and embryonic lethality (~E10.5), demonstrating an essential role in erythroid lineage specification.","method":"Homologous recombination knockout in mice, in vitro yolk sac differentiation, double-mutant ES cell differentiation","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic loss-of-function with defined cellular phenotype, replicated across multiple experimental systems in one study","pmids":["8033210"],"is_preprint":false},{"year":1994,"finding":"LMO2 (RBTN2) protein is not phosphorylated and forms a stable complex with the phosphoprotein TAL1 in the nucleus of erythroid cells; a similar RBTN1–TAL1 complex occurs in a T-cell leukemia line.","method":"Co-immunoprecipitation with anti-RBTN2 and anti-TAL1 antisera from nuclear extracts","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP from endogenous nuclear proteins in erythroid cells; independently consistent with multiple follow-up studies","pmids":["8078932"],"is_preprint":false},{"year":1995,"finding":"LMO2 (RBTN2) directly interacts in vivo and in vitro with GATA1 and GATA2 zinc-finger transcription factors, as well as with TAL1; a quaternary complex of RBTN2, TAL1, GATA1, and E47 can be demonstrated by mammalian two-hybrid analysis.","method":"In vitro GST pulldown, in vivo co-immunoprecipitation, mammalian two-hybrid assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro and in vivo binding confirmed by multiple methods; replicated in companion papers","pmids":["7568177","9209374"],"is_preprint":false},{"year":1996,"finding":"LMO2 and TAL1 form protein dimers specifically in thymocytes of double-transgenic mice (not in single transgenics); co-expression of Lmo2 and Tal1 in T cells causes near-complete thymic repopulation by immature T cells from birth and accelerates T-cell tumor development by ~3 months compared to Lmo2 transgene alone, demonstrating oncogenic synergy through protein interaction.","method":"Transgenic mouse double-mutant analysis, co-immunoprecipitation from thymocytes, thymic phenotyping","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (double transgenic) combined with direct protein interaction evidence and defined cellular phenotype","pmids":["8605871"],"is_preprint":false},{"year":1998,"finding":"LMO2-null ES cells do not contribute to any hematopoietic lineage in adult chimeric mice, demonstrating LMO2 is required for all stages of adult hematopoiesis; re-introduction of an LMO2 expression vector rescues contribution to all lineages, confirming the requirement is cell-autonomous.","method":"ES cell chimera analysis, retroviral rescue experiment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — rigorous loss-of-function plus gain-of-function rescue in vivo with defined lineage phenotype","pmids":["9520463"],"is_preprint":false},{"year":1997,"finding":"LDB1 and LMO2 form a stable endogenous complex in erythroid cells; LDB1 and LMO2 together with SCL/E12 can assemble on SCL-binding DNA sites; forced overexpression of either LDB1 or LMO2 in proerythroblasts inhibits erythroid differentiation, indicating the LDB1/LMO2 complex maintains erythroid precursors in an immature state.","method":"Co-immunoprecipitation from MEL cells, EMSA, forced overexpression in G1ER proerythroblast cells with differentiation readout","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — endogenous complex confirmed by Co-IP, DNA binding shown by EMSA, and functional consequence demonstrated by OE experiment with cellular differentiation readout","pmids":["9391090"],"is_preprint":false},{"year":1998,"finding":"In Lmo2-transgenic T cells, LMO2 forms an oligomeric DNA-binding complex that recognizes a bipartite motif of two E-box sequences ~10 bp apart (distinct from the erythroid complex), specifically in immature CD4−CD8− (double-negative) thymocytes and in T-cell tumors.","method":"EMSA (CASTing), band-shift assays, cell sorting of thymocyte subsets","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — CASTing and EMSA with defined cell-type specificity; mechanistically distinguishes T-cell from erythroid LMO2 complex","pmids":["9707419"],"is_preprint":false},{"year":2000,"finding":"Lmo2-null ES cells contribute normally to the capillary network until E9, but thereafter fail to contribute to endothelial cells of large vessel walls; Lmo2 is not required for de novo vasculogenesis but is necessary for angiogenic remodeling of the existing capillary network into mature vasculature.","method":"Chimeric mouse analysis using Lmo2-null ES cells, histological and endothelial marker analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic loss-of-function in chimeras with stage-specific, lineage-specific phenotypic dissection","pmids":["10618416"],"is_preprint":false},{"year":2007,"finding":"LMO2, together with TAL1 and E47, upregulates VE-cadherin transcription in endothelial cells; knockdown of LMO2 (or TAL1, E47) reduces VE-cadherin mRNA and protein; ectopic co-expression of TAL1, E47, and LMO2 activates VE-cadherin transcription in non-endothelial cells; TAL1, E47, and LMO2 occupy the VE-cadherin promoter at an E-box/GATA motif in HUVECs.","method":"siRNA knockdown, reporter assay, ectopic overexpression, chromatin immunoprecipitation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (KD, OE, ChIP, reporter) establish direct transcriptional regulation of VE-cadherin by the LMO2 complex","pmids":["17242194"],"is_preprint":false},{"year":2007,"finding":"SCL (TAL1) is the predominant interaction partner of LMO2 in hematopoietic cells; the interaction occurs through the loop and helix-2 region of SCL; this interaction nucleates assembly of SCL complexes on DNA, is required for target gene induction and erythroid/megakaryocytic differentiation; furthermore, interaction with SCL prevents LMO2 degradation by the proteasome, thus stabilizing LMO2 protein levels.","method":"Co-immunoprecipitation, mutagenesis of SCL interaction interface, reporter/target gene induction assays, proteasome inhibitor experiments, protein stability assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mutagenesis of binding interface combined with protein stability assays and functional readouts; multiple orthogonal methods in single study","pmids":["17878155"],"is_preprint":false},{"year":2010,"finding":"Crystal structure of LMO2 in complex with the LID domain of LDB1 at 2.4 Å resolution shows LMO2 is largely unstructured and kept in register by LID binding both LIM domains; large conformational movements around a conserved hinge between the LIM domains are observed; this conformational flexibility is necessary for binding of LMO2 to SCL/TAL1 in vitro and for complex function in vivo.","method":"X-ray crystallography, in vitro binding assay, in vivo functional rescue assay, molecular docking","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure at 2.4 Å plus mutagenesis/flexibility validated by in vitro binding and in vivo function in a single rigorous study","pmids":["21076045"],"is_preprint":false},{"year":2013,"finding":"Crystal structure of the (SCL:E47)bHLH:LMO2:LDB1LID complex bound to DNA reveals that LMO2, upon binding SCL, induces new hydrogen bonds within the SCL:E47 heterodimer strengthening it, while imposing a rotation on E47 that weakens E47:DNA contact, shifting main DNA-binding activity to additional partners; this provides the structural basis for LMO2-driven recruitment of the SCL:E47 heterodimer to hematopoietic targets.","method":"X-ray crystallography of pentameric complex, biochemical binding analyses","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure of intact DNA-bound complex combined with biochemical validation; defines molecular mechanism at atomic resolution","pmids":["23831025"],"is_preprint":false},{"year":2010,"finding":"LMO2 induces self-renewal of committed CD4−CD8− thymocytes more than 8 months before overt T-ALL development; these self-renewing thymocytes retain T-cell differentiation capacity but express HSC-typical genes; forced expression of HHEX (one such gene) is sufficient to initiate thymocyte self-renewal in vivo, identifying HHEX as a key downstream effector of Lmo2-induced self-renewal.","method":"Conditional cell fate mapping (lineage tracing), transgenic mouse model, retroviral overexpression of Hhex","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic cell fate mapping plus functional downstream gene validation in vivo; defines mechanism of oncogenic action","pmids":["20093438"],"is_preprint":false},{"year":2011,"finding":"The N-terminal finger of GATA1 simultaneously binds both FOG1 and LMO2; LMO2 in turn can simultaneously contact both GATA1 and SCL/TAL1 at bipartite E-box/WGATAR sites; structural data show FOG1 and TAL1/E2A/LMO2/LDB1 can co-occupy GATA1-dependent gene regulatory elements.","method":"NMR/structural analysis, binding assays, peptide competition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structural data revealing simultaneous binding of two partners to GATA1 N-finger, single study with multiple structural/biochemical validations","pmids":["21844373"],"is_preprint":false},{"year":2016,"finding":"LMO2 is recruited to DNA replication origins by direct interaction with three replication enzymes—DNA polymerase delta (POLD1), DNA primase (PRIM1), and MCM6—and tethering LMO2 to synthetic sequences is sufficient to transform them into replication origins; lowering LMO2 in erythroid progenitors delays G1-S and arrests growth, while ectopic expression in thymocytes drives DNA replication and cell cycle entry.","method":"Co-immunoprecipitation, replication origin-tethering assay, shRNA knockdown with cell cycle analysis, BrdU incorporation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP identifies replication enzyme partners, synthetic origin assay demonstrates sufficiency, loss- and gain-of-function with defined cell cycle phenotypes; multiple orthogonal methods","pmids":["26764384"],"is_preprint":false},{"year":2019,"finding":"LMO2 interacts with 53BP1 during DNA double-strand break repair and thereby inhibits BRCA1 recruitment to DSBs, causing functional homologous recombination deficiency; LMO2-positive DLBCL and T-ALL cells display sensitivity to PARP inhibitors comparable to BRCA1-deficient cells.","method":"Co-immunoprecipitation (LMO2–53BP1 interaction), HR repair assays, PARP inhibitor sensitivity assays, BRCA1 recruitment foci","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct protein interaction plus functional HR assay and pharmacological sensitivity readout; multiple orthogonal methods establishing a new mechanistic role","pmids":["31447348"],"is_preprint":false},{"year":2019,"finding":"LMO2 is deacetylated on lysine residues K74 and K78 via the NAMPT/SIRT2 pathway; deacetylation is required for LMO2 to interact with LDB1 and activate the TAL1 transcriptional complex; NAMPT or SIRT2 inhibition suppresses in vitro growth and in vivo engraftment of T-ALL cells by diminishing LMO2 deacetylation.","method":"Mass spectrometry identification of acetylation sites, mutagenesis of K74/K78, Co-IP of LMO2–LDB1 interaction, NAMPT/SIRT2 inhibitor treatment, mouse engraftment assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — PTM site identified by MS and confirmed by mutagenesis, writer/eraser defined (SIRT2), functional consequence on complex assembly and cellular phenotype demonstrated","pmids":["31366618"],"is_preprint":false},{"year":2014,"finding":"Crystal structure of LMO2 bound to an inhibitory single-domain antibody fragment reveals a conformational change (bending at the central helical hinge between the two LIM domains) compared to the LDB1-bound form; this structural contortion sequesters LMO2 in a non-functional state, suggesting that LMO2 is intrinsically disordered when newly synthesized and adopts its active conformation upon binding a partner protein.","method":"X-ray crystallography, single-domain antibody inhibition assay","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure plus functional inhibition assay; single study with structural and functional validation","pmids":["24407558"],"is_preprint":false},{"year":2006,"finding":"Both LIM domains of LMO2 are required for high-affinity binding to LDB1 (Kd ~20 nM); the first LIM domain primarily mediates this interaction while the second increases affinity ~10-fold; LMO2 binds LDB1 with ~2-fold lower affinity than does LMO4, implying that elevated LMO2 levels rather than intrinsically higher affinity drive LDB1 sequestration in leukemia.","method":"ELISA-based binding assay, protein engineering, mutagenesis, yeast two-hybrid analysis, phage display","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — quantitative binding affinities measured by ELISA, validated by mutagenesis and yeast two-hybrid; multiple orthogonal methods","pmids":["16616188"],"is_preprint":false},{"year":2005,"finding":"Human BEX2 specifically interacts with LMO2 (confirmed by GST pulldown and Co-IP) and is part of a DNA-binding complex with LMO2 as demonstrated by EMSA; BEX2 enhances LMO2 transcriptional activity in vivo; a neuronal bHLH protein NSCL2 was identified as an additional LMO2-binding partner, and LMO2 upregulates NSCL2-dependent transcription, augmented by BEX2.","method":"GST pulldown, co-immunoprecipitation, EMSA, mammalian two-hybrid, reporter assay","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple binding methods (pulldown + Co-IP + EMSA) and functional reporter assay in single lab study","pmids":["16314316"],"is_preprint":false},{"year":2008,"finding":"An anti-LMO2 single-chain Fv antibody binds LMO2 through its third and fourth LIM finger structures (LIM2 domain); intracellular expression inhibits Lmo2-dependent erythropoiesis but not endothelial development; it also inhibits Lmo2-dependent leukemia in a mouse T-cell tumor transplantation assay.","method":"Intracellular antibody capture technology, vector-mediated intracellular expression, erythropoiesis assay, mouse tumor transplantation assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional inhibition by specific intracellular antibody with defined binding site, two distinct functional readouts; single lab","pmids":["18438427"],"is_preprint":false},{"year":2013,"finding":"Lmo2 requires Lyl1 (not Scl/Tal1) to mediate its leukemic functions in the thymus; Lyl1 deletion in Lmo2-transgenic mice abolishes all oncogenic functions including HSC-like gene signature upregulation, thymocyte self-renewal, and T-ALL development; Scl deletion has no effect. LMO2 and LYL1 are co-expressed in ETP-ALL patient samples and LYL1 is required for growth of ETP-ALL cell lines.","method":"Conditional double-knockout transgenic mouse model (Lmo2-Tg × Scl-cKO or Lyl1-cKO), shRNA knockdown of LYL1 in human cell lines, gene expression profiling","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in mice with defined phenotype plus human cell line validation; demonstrates obligate partner specificity","pmids":["23926305"],"is_preprint":false},{"year":2003,"finding":"Conditional knockout of Lmo2 using Rag1-, CD19-, or Lck-Cre drivers causes efficient Lmo2 deletion in early lymphoid progenitors but produces no disturbance of T- or B-cell lymphopoiesis, establishing that LMO2 has no mandatory role in normal T- or B-cell development.","method":"Conditional knockout mice (loxP/Cre system), flow cytometry of lymphoid populations","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean conditional KO with efficient deletion confirmed; negative result is mechanistically informative and clearly established","pmids":["14645513"],"is_preprint":false},{"year":2010,"finding":"TAL1's DNA-binding activity is not required for cooperation with LMO2 in T-cell leukemia; Tal1/Lmo2 and MutTAL1/Lmo2 bitransgenic mice develop leukemia with identical kinetics; both reduce E47/HEB transcriptional activity, suggesting LMO2 cooperates with TAL1 to interfere with E47/HEB transcriptional functions rather than to activate target genes directly.","method":"Double-transgenic mouse model with DNA-binding mutant TAL1, leukemia onset comparison, E47/HEB reporter assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in mice with mechanistic reporter assays; single lab, single study","pmids":["21057528"],"is_preprint":false},{"year":1995,"finding":"The NH2-terminal regions of RBTN1 and RBTN2 (LMO2) are capable of supporting transcriptional transactivation; using Isl-1 homeodomain fusions and yeast assays, the first 27 amino acids of RBTN2 are sufficient for transactivation, and RBTN2 forms homodimers in yeast.","method":"Reporter transfection assay, yeast two-hybrid assay, Isl-1 homeodomain fusion constructs","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter and yeast two-hybrid assays; single lab, defines N-terminal transactivation domain and homodimerization","pmids":["7731680"],"is_preprint":false},{"year":2005,"finding":"LMO2 LIM2 domain deletion abolishes binding to GATA proteins (while LIM1 deletion does not); overexpression of LMO2 with mutant LIM2 but intact LIM1 causes dominant-negative inhibition of fetal hematopoiesis in transgenic mice (fetal death, small livers, decreased hematopoiesis) and inhibits DMSO-induced erythroid differentiation in MEL cells.","method":"Co-immunoprecipitation with LIM-domain deletion/mutation constructs, transgenic mouse hematopoiesis analysis, MEL cell differentiation assay","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain mapping by Co-IP combined with in vivo and in vitro dominant-negative phenotype; single lab","pmids":["15911088"],"is_preprint":false},{"year":2017,"finding":"LMO2 is required at the haemangioblast stage to position the TAL1/LMO2/LDB1 complex to regulatory elements important for establishing the haematopoietic developmental program; in the absence of LMO2, TAL1 target-site recognition genome-wide is impaired; TAL1 also sustains Lmo2 expression at this stage.","method":"Lmo2−/− ES cell differentiation to haemangioblasts, ChIP-seq (TAL1, LMO2, LDB1), genome-wide gene expression analysis, comparison with Tal1−/− cells","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq in defined loss-of-function cells revealing stage-specific cistrome requirements; multiple orthogonal genomics methods","pmids":["28973433"],"is_preprint":false},{"year":2013,"finding":"GATA2 and LMO2 form transcriptional complexes in endothelial cells and directly regulate neuropilin-2 (NRP2) gene expression; knockdown of either GATA2 or LMO2 inhibits VEGF-induced angiogenesis and NRP2 promoter activity; NRP2 overexpression partially rescues the knockdown phenotype.","method":"siRNA knockdown, promoter reporter assay, ChIP, angiogenesis sprouting assay, rescue by NRP2 overexpression","journal":"Angiogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter plus rescue demonstrate direct transcriptional regulation; single lab","pmids":["23892628"],"is_preprint":false},{"year":2012,"finding":"Angiopoietin-2 (ANG-2) is a direct transcriptional target of LMO2, TAL1, LYL1, and GATA2 in endothelial cells; LMO2 assembles TAL1-E47, LYL1-LYL1, and/or LYL1-TAL1 dimers with GATA2 at a conserved Ebox-GATA composite element in the ANG-2 promoter; ChIP confirms occupancy of this element.","method":"siRNA knockdown, ChIP, reporter assay, ectopic co-expression in non-endothelial cells","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (KD, ChIP, reporter, OE) establish direct regulation; single lab","pmids":["22792348"],"is_preprint":false},{"year":2010,"finding":"c-Myb directly binds the LMO2 promoter and transactivates LMO2 expression; LMO2 (along with KLF1) overexpression partially rescues the erythroid differentiation defect caused by c-Myb silencing in human CD34+ cells.","method":"Chromatin immunoprecipitation, luciferase reporter assay, retroviral overexpression rescue, c-Myb siRNA knockdown","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter establishes direct transcriptional regulation; rescue experiment confirms functional relevance; single lab","pmids":["20686118"],"is_preprint":false},{"year":2017,"finding":"Lmo2 directly regulates Sphk1 (sphingosine kinase 1) gene expression in endothelial cells by binding the Sphk1 promoter (shown by ChIP-PCR); Lmo2 KD reduces Sphk1 expression; Sphk1 mRNA rescues impaired intersegmental vessel formation and endothelial cell migration in Lmo2-KD zebrafish and human cells.","method":"Morpholino knockdown in zebrafish, siRNA in HUVECs, ChIP-PCR, scratch migration assay, mRNA rescue","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-PCR demonstrates direct promoter binding, KD and rescue confirm functional epistasis; single lab with in vivo and in vitro methods","pmids":["28775072"],"is_preprint":false},{"year":2021,"finding":"Lmo2 directly binds the promoter of prdm16 in endothelial cells (shown by ChIP-PCR); lmo2 loss-of-function zebrafish mutants show reduced prdm16 expression and impaired angiogenesis; Prdm16 KD phenocopies lmo2 mutant vascular defects, defining an Lmo2–Prdm16 axis in angiogenesis.","method":"ChIP-PCR, lmo2 loss-of-function zebrafish mutants, morpholino KD, endothelial cell differentiation/migration assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-PCR plus loss-of-function genetics; single lab but in vivo and in vitro methods","pmids":["34330825"],"is_preprint":false},{"year":2017,"finding":"In basal-type breast cancer cells, LMO2 localizes predominantly to the cytoplasm and interacts with cofilin-1, a regulator of actin cytoskeleton dynamics; this interaction promotes tumor cell migration, invasion, and metastasis in vivo.","method":"Co-immunoprecipitation (LMO2–cofilin1), subcellular fractionation/immunofluorescence, migration/invasion assays, SCID mouse metastasis model","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP plus localization plus functional cellular assays; single lab, but multiple orthogonal readouts","pmids":["27880729"],"is_preprint":false},{"year":2016,"finding":"In breast and colorectal cancer cells, LMO2 localizes to the cytoplasm and binds to the PDZ domain of Dishevelled-1/2 (DVL-1/2); this interaction attenuates canonical Wnt/β-catenin signaling; LMO2 downregulation increases cell proliferation and reduces apoptosis in these cells.","method":"Co-immunoprecipitation (LMO2–DVL1/2), β-catenin activity assay, LMO2 overexpression and knockdown with proliferation/apoptosis readouts","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP identifies cytoplasmic interaction partner; functional assays show pathway consequence; single lab","pmids":["27779255"],"is_preprint":false},{"year":2018,"finding":"LMO2 recruits SAP18 and HDAC1 to form an epigenetic regulatory complex on the ZEB1 promoter, inducing histone deacetylation and transcriptional repression of ZEB1; ZEB1 downregulation increases leukemia stem cell phenotype and reduces sensitivity to methotrexate in T-ALL; HDAC inhibitor TSA restores chemosensitivity.","method":"Co-immunoprecipitation (LMO2–SAP18–HDAC1), ChIP at ZEB1 promoter, HDAC inhibitor treatment, shRNA knockdown, leukemia stem cell assays","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP establishes complex, ChIP confirms promoter occupancy, pharmacological rescue links HDAC activity to phenotype; single lab","pmids":["29778661"],"is_preprint":false},{"year":2021,"finding":"LMO2 directly binds the Bcl11a and Tcf7 loci in pro-B cells; LMO2 is required to maintain T-lineage potential in pre-thymic progenitors; CRISPR/Cas9 deletion of Lmo2 abolishes T-lineage potential; ectopic Lmo2 expression restores this potential by enabling Bcl11a and Tcf7 expression.","method":"CRISPR/Cas9 knockout, ChIP (LMO2 at Bcl11a and Tcf7 loci), ectopic expression rescue, in vitro T-cell differentiation assay","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP identifies direct target loci, CRISPR KO and rescue confirm functional requirement; single lab","pmids":["34382935"],"is_preprint":false},{"year":2014,"finding":"HHEX is a direct transcriptional target of LMO2 in T-ALL; conditional inactivation of Hhex in CD2-Lmo2 transgenic mice markedly attenuates T-ALL development, establishing HHEX as a crucial mediator of Lmo2's oncogenic function.","method":"ChIP (LMO2 at HHEX locus), conditional Hhex knockout in Lmo2-transgenic mice, T-ALL incidence analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus conditional genetic epistasis demonstrate direct transcriptional target and functional requirement; single lab","pmids":["24465765"],"is_preprint":false},{"year":2009,"finding":"miR-223 binds the 3' UTR of LMO2 and reduces LMO2 mRNA and protein levels; enforced expression of miR-223 impairs erythroid differentiation, phenocopied by LMO2 siRNA knockdown; the decline of miR-223 during erythropoiesis is required to allow LMO2 upregulation and erythroid commitment.","method":"3' UTR luciferase reporter assay, miR-223 overexpression, LMO2 siRNA knockdown, erythroid colony assay","journal":"Haematologica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct 3' UTR binding validated by reporter, loss-of-function of LMO2 phenocopies miRNA OE; single lab","pmids":["19278969"],"is_preprint":false},{"year":2005,"finding":"The LMO2 proximal promoter is active in hematopoietic progenitor and endothelial cell lines in a manner dependent on three conserved ETS-binding sites bound in vivo by ELF1, FLI1, and ETS1; transgenic analysis confirms the proximal promoter drives expression in endothelial cells in vivo but additional enhancers are needed for hematopoietic expression.","method":"Comparative genomics, transient and stable transfections, ChIP, transgenic mouse analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms in vivo factor binding to LMO2 promoter, transgenic mice validate tissue specificity; single lab","pmids":["15994290"],"is_preprint":false},{"year":2021,"finding":"LMO2 is identified as an AR (androgen receptor) target gene in prostate fibroblasts; AR directly represses LMO2 through binding to androgen response elements (AREs) in the LMO2 locus (ChIP-seq); upon AR deactivation, LMO2 overexpression in fibroblasts promotes castration-resistant PCa cell growth non-cell-autonomously via paracrine IL-11 and FGF-9.","method":"ChIP-seq (AR binding at LMO2 locus), LMO2 knockdown and overexpression, paracrine co-culture experiments, cytokine neutralization","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq establishes direct AR repression, functional non-cell-autonomous signaling confirmed by co-culture and paracrine factor experiments; single lab","pmids":["33503448"],"is_preprint":false}],"current_model":"LMO2 is a LIM-only scaffold protein that functions as an obligatory bridging component of multiprotein transcriptional complexes—most prominently a pentameric complex containing TAL1/SCL, E47, GATA-1, and LDB1 that binds bipartite E-box/GATA DNA motifs—where its conformational flexibility enables partner-induced structural ordering; SCL interaction stabilizes LMO2 from proteasomal degradation; deacetylation on K74/K78 by SIRT2 (via NAMPT) is required for LDB1 engagement; the complex directly activates erythroid, endothelial, and hematopoietic stem-cell target genes (including VE-cadherin, ANG-2, HHEX, Sphk1, Prdm16, Bcl11a, and Tcf7), while LMO2 also interfaces with DNA replication machinery (POLD1, PRIM1, MCM6) to promote S-phase entry, and in certain solid-tumor contexts localizes to the cytoplasm where it interacts with DVL-1/2 (attenuating Wnt/β-catenin) or cofilin-1 (promoting cytoskeletal remodeling), and in DLBCL interacts with 53BP1 to block BRCA1 recruitment and impair homologous recombination repair."},"narrative":{"mechanistic_narrative":"LMO2 is a nuclear LIM-only protein that functions as an obligatory bridging scaffold within multiprotein transcription complexes governing erythroid, endothelial, and hematopoietic stem-cell programs [PMID:9214632, PMID:8033210]. In erythroid cells it nucleates a pentameric DNA-binding complex with TAL1/SCL, E47/E2A, GATA-1, and LDB1/NLI that recognizes a bipartite E-box/GATA composite motif and transactivates target genes [PMID:9214632, PMID:7568177, PMID:9209374], and it likewise bridges GATA1 simultaneously with TAL1/E2A at GATA-dependent regulatory elements [PMID:21844373]. Structurally, LMO2 is intrinsically disordered when newly synthesized and acquires its active conformation upon partner binding: the LID domain of LDB1 holds both LIM domains in register through a flexible hinge, and this conformational plasticity is required for SCL/TAL1 engagement and complex function [PMID:21076045, PMID:24407558, PMID:16616188]. Binding of SCL strengthens the SCL:E47 heterodimer while shifting DNA contact to partner factors, defining the atomic basis for complex recruitment to hematopoietic targets [PMID:23831025], and SCL interaction additionally protects LMO2 from proteasomal degradation [PMID:17878155]. Deacetylation of LMO2 on K74/K78 by the NAMPT/SIRT2 pathway is required for LDB1 engagement and complex activation [PMID:31366618]. Through this complex LMO2 directly activates target genes including VE-cadherin, NRP2, ANG-2, Sphk1, Prdm16, Bcl11a, and Tcf7 to drive endothelial remodeling, hematopoietic specification, and lymphoid lineage potential [PMID:17242194, PMID:23892628, PMID:22792348, PMID:28775072, PMID:34330825, PMID:34382935], and is genetically essential for yolk-sac erythropoiesis, all adult hematopoiesis, and angiogenic vascular remodeling [PMID:8033210, PMID:9520463, PMID:10618416]. LMO2 is a potent oncogene: ectopic expression drives self-renewal of immature thymocytes and T-ALL through downstream effectors HHEX and the obligate partner LYL1 (rather than SCL) [PMID:20093438, PMID:23926305, PMID:24465765]. Beyond transcription, LMO2 is recruited to DNA replication origins via POLD1, PRIM1, and MCM6 to promote S-phase entry [PMID:26764384], and in DLBCL it interacts with 53BP1 to block BRCA1 recruitment, conferring homologous-recombination deficiency and PARP-inhibitor sensitivity [PMID:31447348]. In solid-tumor contexts LMO2 can localize to the cytoplasm, where it binds cofilin-1 to promote migration and invasion, or DVL-1/2 to attenuate Wnt/β-catenin signaling [PMID:27880729, PMID:27779255].","teleology":[{"year":1994,"claim":"Established LMO2 as a nuclear erythroid-lineage protein with a non-redundant developmental requirement, defining its biological importance before its molecular activity was known.","evidence":"Homozygous knockout in mice with in vitro yolk-sac differentiation; reciprocal Co-IP of endogenous nuclear proteins","pmids":["8033210","8078932"],"confidence":"High","gaps":["Did not define the molecular mechanism by which LMO2 acts","Embryonic lethality precluded analysis of adult and other lineages"]},{"year":1995,"claim":"Identified the partner network by showing LMO2 binds GATA1/GATA2 and TAL1 and can form a quaternary complex with E47, establishing LMO2 as a multivalent protein-interaction hub.","evidence":"GST pulldown, in vivo Co-IP, and mammalian two-hybrid; plus reporter and yeast assays defining an N-terminal transactivation region and homodimerization","pmids":["7568177","9209374","7731680"],"confidence":"High","gaps":["Did not establish DNA-binding specificity of the assembled complex","N-terminal transactivation function not validated in the native complex context"]},{"year":1997,"claim":"Defined the core erythroid mechanism: LMO2 bridges a pentameric TAL1/E47/GATA-1/LDB1 complex onto a bipartite E-box/GATA motif to transactivate transcription, resolving how the partners cooperate on DNA.","evidence":"Co-IP, EMSA/CASTing, mammalian two-hybrid, reporter transactivation; endogenous LDB1–LMO2 complex with overexpression differentiation readout","pmids":["9214632","9391090"],"confidence":"High","gaps":["Did not reveal the structural basis of assembly","Direct endogenous target genes not yet identified"]},{"year":1998,"claim":"Showed LMO2 is cell-autonomously required for all adult hematopoietic lineages and, separately, that an oligomeric LMO2 complex recognizing a distinct double-E-box motif forms in immature thymocytes, distinguishing physiological from leukemic complexes.","evidence":"ES-cell chimera analysis with retroviral rescue; EMSA/CASTing with thymocyte subset sorting","pmids":["9520463","9707419"],"confidence":"High","gaps":["The composition of the thymic double-E-box complex was not fully resolved","Did not identify downstream effectors of the leukemic complex"]},{"year":2000,"claim":"Dissected the vascular role, establishing LMO2 is dispensable for vasculogenesis but required for angiogenic remodeling of the capillary network into mature vessels.","evidence":"Chimeric mouse analysis with Lmo2-null ES cells and endothelial marker histology","pmids":["10618416"],"confidence":"High","gaps":["Did not identify the endothelial target genes mediating remodeling","Mechanistic basis of the stage-specific requirement unresolved"]},{"year":2006,"claim":"Quantified LMO2–LDB1 binding, showing both LIM domains contribute and that LMO2 binds with lower affinity than LMO4, implying leukemic LDB1 sequestration is driven by elevated LMO2 levels rather than higher intrinsic affinity.","evidence":"ELISA-based affinity measurement, protein engineering, mutagenesis, yeast two-hybrid, phage display","pmids":["16616188"],"confidence":"High","gaps":["Did not address how affinity translates into in vivo complex selectivity","Other LIM-domain partner affinities not compared"]},{"year":2007,"claim":"Identified the first direct endothelial target and the central role of SCL, showing the LMO2/TAL1/E47 complex occupies and activates the VE-cadherin promoter and that SCL stabilizes LMO2 from proteasomal degradation.","evidence":"siRNA, ChIP, reporter and ectopic expression; mutagenesis of the SCL interface plus proteasome inhibition and protein-stability assays","pmids":["17242194","17878155"],"confidence":"High","gaps":["Did not define the degradation machinery acting on free LMO2","Generality of the stabilization mechanism across cell types not tested"]},{"year":2010,"claim":"Provided the structural and oncogenic mechanism: a 2.4 Å LMO2–LDB1 LID structure revealed LMO2 is largely unstructured and held in register by LID, with hinge flexibility required for SCL binding; in parallel, LMO2 was shown to drive thymocyte self-renewal through the downstream effector HHEX.","evidence":"X-ray crystallography with in vitro binding and in vivo rescue; lineage-tracing transgenic model with retroviral Hhex expression","pmids":["21076045","20093438"],"confidence":"High","gaps":["Structure of the full DNA-bound complex not yet solved","How HHEX maintains self-renewal mechanistically not defined"]},{"year":2013,"claim":"Resolved the atomic basis of target recruitment and the obligate leukemic partner, showing the DNA-bound (SCL:E47):LMO2:LDB1 structure where LMO2 reshapes the SCL:E47 heterodimer, and that Lyl1—not Scl—is required for Lmo2's leukemic functions.","evidence":"X-ray crystallography of the pentameric DNA-bound complex; conditional double-knockout mice with human ETP-ALL cell-line validation","pmids":["23831025","23926305"],"confidence":"High","gaps":["Why Lyl1 substitutes for Scl in leukemia at the structural level unresolved","Cistrome differences between Scl- and Lyl1-containing complexes not mapped"]},{"year":2014,"claim":"Reinforced the conformational-switch model with a structure of LMO2 bent at the LIM hinge by an inhibitory antibody, and identified HHEX as a direct LMO2 target genetically required for T-ALL.","evidence":"X-ray crystallography with single-domain antibody inhibition; ChIP plus conditional Hhex knockout in Lmo2-transgenic mice","pmids":["24407558","24465765"],"confidence":"High","gaps":["The native unbound conformation in cells not directly observed","Full set of HHEX-dependent leukemic targets unknown"]},{"year":2016,"claim":"Extended LMO2 beyond transcription to DNA replication, showing direct binding to POLD1, PRIM1, and MCM6 recruits LMO2 to origins and is sufficient to convert synthetic sequences into replication origins driving S-phase entry.","evidence":"Co-IP, replication-origin tethering assay, shRNA with cell-cycle analysis, BrdU incorporation","pmids":["26764384"],"confidence":"High","gaps":["How origin recruitment is coordinated with the transcriptional role unclear","Whether DNA binding by the complex is required for origin function not resolved"]},{"year":2017,"claim":"Defined LMO2's genome-wide cistrome role at the haemangioblast stage—positioning the TAL1/LMO2/LDB1 complex at hematopoietic regulatory elements—and identified a cytoplasmic, non-transcriptional function via cofilin-1 in invasive breast cancer.","evidence":"ChIP-seq in Lmo2-null haemangioblasts; Co-IP, fractionation, migration/invasion assays and a SCID metastasis model","pmids":["28973433","27880729"],"confidence":"High","gaps":["Switch between nuclear scaffold and cytoplasmic cofilin functions not mechanistically defined","Cofilin interaction validated in a single cancer context"]},{"year":2019,"claim":"Uncovered post-translational and DNA-repair mechanisms: K74/K78 deacetylation by NAMPT/SIRT2 is required for LDB1 engagement and complex activation, and LMO2–53BP1 interaction blocks BRCA1 recruitment to confer HR deficiency and PARP-inhibitor sensitivity.","evidence":"Mass spectrometry, mutagenesis, Co-IP, NAMPT/SIRT2 inhibitor and engraftment assays; HR repair assays, BRCA1 foci and PARP-inhibitor sensitivity","pmids":["31366618","31447348"],"confidence":"High","gaps":["The acetyltransferase that opposes SIRT2 on LMO2 not identified","How nuclear LMO2 is partitioned between transcription and 53BP1-bound DSBs unknown"]},{"year":2021,"claim":"Connected LMO2 to lineage-decision and angiogenic target genes, showing direct binding to Bcl11a/Tcf7 to maintain T-lineage potential and to prdm16 in endothelial angiogenesis, alongside an AR-repressed paracrine role in prostate cancer.","evidence":"CRISPR knockout with ChIP and rescue in pro-B cells; ChIP-PCR with zebrafish loss-of-function for prdm16; AR ChIP-seq with paracrine co-culture","pmids":["34382935","34330825","33503448"],"confidence":"Medium","gaps":["Whether these targets are bound as part of the canonical pentameric complex not always defined","Single-lab studies awaiting independent confirmation"]},{"year":null,"claim":"How LMO2's distinct activities—nuclear transcriptional scaffolding, replication-origin licensing, 53BP1-mediated repair inhibition, and cytoplasmic cofilin/DVL interactions—are partitioned and regulated within a single cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model coordinating nuclear-transcriptional, replication, repair, and cytoplasmic functions","Signals controlling nuclear versus cytoplasmic localization not defined","Acetyltransferase opposing SIRT2 and full degradation machinery for free LMO2 unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,6,9]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,3,14]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[33]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,2]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[33,34]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,9,29]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,5,8]},{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[15]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[16]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[13,22,16]}],"complexes":["TAL1/SCL-E47-GATA1-LDB1 pentameric complex","LMO2-LDB1 complex","LMO2-SAP18-HDAC1 repressor complex"],"partners":["TAL1","LDB1","GATA1","E47","LYL1","53BP1","POLD1","DVL1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P25791","full_name":"Rhombotin-2","aliases":["Cysteine-rich protein TTG-2","LIM domain only protein 2","LMO-2","T-cell translocation protein 2"],"length_aa":158,"mass_kda":18.4,"function":"Acts with TAL1/SCL to regulate red blood cell development. Also acts with LDB1 to maintain erythroid precursors in an immature state","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P25791/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LMO2","classification":"Not Classified","n_dependent_lines":27,"n_total_lines":1208,"dependency_fraction":0.022350993377483443},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LMO2","total_profiled":1310},"omim":[{"mim_id":"619798","title":"E74-LIKE ETS TRANSCRIPTION FACTOR 2; ELF2","url":"https://www.omim.org/entry/619798"},{"mim_id":"616792","title":"NEUROBLASTOMA, SUSCEPTIBILITY TO, 7; NBLST7","url":"https://www.omim.org/entry/616792"},{"mim_id":"610931","title":"ZINC FINGER GENE IN AUTOIMMUNE THYROID DISEASE 1; ZFAT1","url":"https://www.omim.org/entry/610931"},{"mim_id":"609373","title":"LYSINE DEMETHYLASE 3B; KDM3B","url":"https://www.omim.org/entry/609373"},{"mim_id":"609358","title":"ETS VARIANT TRANSCRIPTION FACTOR 2; ETV2","url":"https://www.omim.org/entry/609358"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/LMO2"},"hgnc":{"alias_symbol":["TTG2","RHOM2","RBTN2"],"prev_symbol":["RBTNL1"]},"alphafold":{"accession":"P25791","domains":[{"cath_id":"2.10.110.10","chopping":"1-86","consensus_level":"high","plddt":87.1395,"start":1,"end":86},{"cath_id":"2.10.110.10","chopping":"91-154","consensus_level":"medium","plddt":95.8897,"start":91,"end":154}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P25791","model_url":"https://alphafold.ebi.ac.uk/files/AF-P25791-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P25791-F1-predicted_aligned_error_v6.png","plddt_mean":90.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LMO2","jax_strain_url":"https://www.jax.org/strain/search?query=LMO2"},"sequence":{"accession":"P25791","fasta_url":"https://rest.uniprot.org/uniprotkb/P25791.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P25791/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P25791"}},"corpus_meta":[{"pmid":"14564000","id":"PMC_14564000","title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.","date":"2003","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/14564000","citation_count":2787,"is_preprint":false},{"pmid":"9214632","id":"PMC_9214632","title":"The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9214632","citation_count":737,"is_preprint":false},{"pmid":"8033210","id":"PMC_8033210","title":"The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development.","date":"1994","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8033210","citation_count":540,"is_preprint":false},{"pmid":"1923511","id":"PMC_1923511","title":"TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11).","date":"1991","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1923511","citation_count":258,"is_preprint":false},{"pmid":"9520463","id":"PMC_9520463","title":"The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9520463","citation_count":254,"is_preprint":false},{"pmid":"8078932","id":"PMC_8078932","title":"The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8078932","citation_count":205,"is_preprint":false},{"pmid":"20093438","id":"PMC_20093438","title":"The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal.","date":"2010","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20093438","citation_count":192,"is_preprint":false},{"pmid":"8605871","id":"PMC_8605871","title":"Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8605871","citation_count":178,"is_preprint":false},{"pmid":"7568177","id":"PMC_7568177","title":"Association of erythroid transcription factors: complexes involving the LIM protein RBTN2 and the zinc-finger protein GATA1.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7568177","citation_count":177,"is_preprint":false},{"pmid":"10618416","id":"PMC_10618416","title":"The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10618416","citation_count":147,"is_preprint":false},{"pmid":"14602685","id":"PMC_14602685","title":"Lmo2 and Scl/Tal1 convert non-axial mesoderm into haemangioblasts which differentiate into endothelial cells in the absence of Gata1.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/14602685","citation_count":142,"is_preprint":false},{"pmid":"9391090","id":"PMC_9391090","title":"The LIM-domain binding protein Ldb1 and its partner LMO2 act as negative regulators of erythroid differentiation.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9391090","citation_count":138,"is_preprint":false},{"pmid":"17038524","id":"PMC_17038524","title":"The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17038524","citation_count":135,"is_preprint":false},{"pmid":"19278969","id":"PMC_19278969","title":"MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis.","date":"2009","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/19278969","citation_count":120,"is_preprint":false},{"pmid":"17090656","id":"PMC_17090656","title":"The transcription factors Scl and Lmo2 act together during development of the hemangioblast in zebrafish.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17090656","citation_count":118,"is_preprint":false},{"pmid":"14645513","id":"PMC_14645513","title":"The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14645513","citation_count":117,"is_preprint":false},{"pmid":"1461647","id":"PMC_1461647","title":"T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes.","date":"1992","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1461647","citation_count":112,"is_preprint":false},{"pmid":"28105033","id":"PMC_28105033","title":"A Grapevine TTG2-Like WRKY Transcription Factor Is Involved in Regulating Vacuolar Transport and Flavonoid Biosynthesis.","date":"2017","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/28105033","citation_count":99,"is_preprint":false},{"pmid":"16260184","id":"PMC_16260184","title":"The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion.","date":"2005","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16260184","citation_count":95,"is_preprint":false},{"pmid":"9707419","id":"PMC_9707419","title":"The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells.","date":"1998","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9707419","citation_count":94,"is_preprint":false},{"pmid":"20686118","id":"PMC_20686118","title":"c-myb supports erythropoiesis through the transactivation of KLF1 and LMO2 expression.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20686118","citation_count":93,"is_preprint":false},{"pmid":"20457870","id":"PMC_20457870","title":"A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20457870","citation_count":91,"is_preprint":false},{"pmid":"20856265","id":"PMC_20856265","title":"miR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP-β.","date":"2010","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/20856265","citation_count":87,"is_preprint":false},{"pmid":"7970726","id":"PMC_7970726","title":"T cell tumours of disparate phenotype in mice transgenic for Rbtn-2.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7970726","citation_count":86,"is_preprint":false},{"pmid":"10631184","id":"PMC_10631184","title":"Lmo2 and GATA-3 associated expression in intraembryonic hemogenic sites.","date":"2000","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10631184","citation_count":86,"is_preprint":false},{"pmid":"15893977","id":"PMC_15893977","title":"Regulation of the lmo2 promoter during hematopoietic and vascular development in zebrafish.","date":"2005","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/15893977","citation_count":82,"is_preprint":false},{"pmid":"9116269","id":"PMC_9116269","title":"Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) and Tal-1 (SCL).","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9116269","citation_count":82,"is_preprint":false},{"pmid":"7545805","id":"PMC_7545805","title":"The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7545805","citation_count":78,"is_preprint":false},{"pmid":"28270453","id":"PMC_28270453","title":"Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28270453","citation_count":68,"is_preprint":false},{"pmid":"19171877","id":"PMC_19171877","title":"Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19171877","citation_count":66,"is_preprint":false},{"pmid":"17242194","id":"PMC_17242194","title":"TAL-1/SCL and its partners E47 and LMO2 up-regulate VE-cadherin expression in endothelial cells.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17242194","citation_count":66,"is_preprint":false},{"pmid":"31447348","id":"PMC_31447348","title":"LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.","date":"2019","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/31447348","citation_count":64,"is_preprint":false},{"pmid":"26108219","id":"PMC_26108219","title":"LMO2 at 25 years: a paradigm of chromosomal translocation proteins.","date":"2015","source":"Open biology","url":"https://pubmed.ncbi.nlm.nih.gov/26108219","citation_count":60,"is_preprint":false},{"pmid":"23926305","id":"PMC_23926305","title":"Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23926305","citation_count":60,"is_preprint":false},{"pmid":"21076045","id":"PMC_21076045","title":"Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21076045","citation_count":60,"is_preprint":false},{"pmid":"23831025","id":"PMC_23831025","title":"Structural basis for LMO2-driven recruitment of the SCL:E47bHLH heterodimer to hematopoietic-specific transcriptional targets.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23831025","citation_count":57,"is_preprint":false},{"pmid":"24465765","id":"PMC_24465765","title":"LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24465765","citation_count":51,"is_preprint":false},{"pmid":"15994290","id":"PMC_15994290","title":"Fli1, Elf1, and Ets1 regulate the proximal promoter of the LMO2 gene in endothelial cells.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15994290","citation_count":51,"is_preprint":false},{"pmid":"17167821","id":"PMC_17167821","title":"The significance of LMO2 expression in the progression of prostate cancer.","date":"2007","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17167821","citation_count":48,"is_preprint":false},{"pmid":"23892628","id":"PMC_23892628","title":"GATA2 and Lmo2 control angiogenesis and lymphangiogenesis via direct transcriptional regulation of neuropilin-2.","date":"2013","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23892628","citation_count":47,"is_preprint":false},{"pmid":"10197599","id":"PMC_10197599","title":"The effect of chromosomal translocations in acute leukemias: the LMO2 paradigm in transcription and development.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10197599","citation_count":47,"is_preprint":false},{"pmid":"23378057","id":"PMC_23378057","title":"Lmo2 induces hematopoietic stem cell-like features in T-cell progenitor cells prior to leukemia.","date":"2013","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/23378057","citation_count":46,"is_preprint":false},{"pmid":"9204936","id":"PMC_9204936","title":"Expression of LIM protein genes Lmo1, Lmo2, and Lmo3 in adult mouse hippocampus and other forebrain regions: differential regulation by seizure activity.","date":"1997","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/9204936","citation_count":45,"is_preprint":false},{"pmid":"11857074","id":"PMC_11857074","title":"The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11857074","citation_count":44,"is_preprint":false},{"pmid":"25721045","id":"PMC_25721045","title":"The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells.","date":"2015","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/25721045","citation_count":41,"is_preprint":false},{"pmid":"21844373","id":"PMC_21844373","title":"Structural basis of simultaneous recruitment of the transcriptional regulators LMO2 and FOG1/ZFPM1 by the transcription factor GATA1.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21844373","citation_count":41,"is_preprint":false},{"pmid":"26071533","id":"PMC_26071533","title":"Expression of Brassica napus TTG2, a regulator of trichome development, increases plant sensitivity to salt stress by suppressing the expression of auxin biosynthesis genes.","date":"2015","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/26071533","citation_count":39,"is_preprint":false},{"pmid":"18438427","id":"PMC_18438427","title":"An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18438427","citation_count":38,"is_preprint":false},{"pmid":"7731686","id":"PMC_7731686","title":"The TTG-2/RBTN2 T cell oncogene encodes two alternative transcripts from two promoters: the distal promoter is removed by most 11p13 translocations in acute T cell leukaemia's (T-ALL).","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7731686","citation_count":37,"is_preprint":false},{"pmid":"19487290","id":"PMC_19487290","title":"Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19487290","citation_count":36,"is_preprint":false},{"pmid":"17878155","id":"PMC_17878155","title":"Protein stability and transcription factor complex assembly determined by the SCL-LMO2 interaction.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17878155","citation_count":35,"is_preprint":false},{"pmid":"16314316","id":"PMC_16314316","title":"Human Bex2 interacts with LMO2 and regulates the transcriptional activity of a novel DNA-binding complex.","date":"2005","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16314316","citation_count":35,"is_preprint":false},{"pmid":"20676125","id":"PMC_20676125","title":"A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20676125","citation_count":35,"is_preprint":false},{"pmid":"20697248","id":"PMC_20697248","title":"Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components.","date":"2010","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20697248","citation_count":35,"is_preprint":false},{"pmid":"29880602","id":"PMC_29880602","title":"Lmo2 expression defines tumor cell identity during T-cell leukemogenesis.","date":"2018","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/29880602","citation_count":34,"is_preprint":false},{"pmid":"20519628","id":"PMC_20519628","title":"Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20519628","citation_count":34,"is_preprint":false},{"pmid":"20861166","id":"PMC_20861166","title":"The molecular basis of Lmo2-induced T-cell acute lymphoblastic leukemia.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20861166","citation_count":33,"is_preprint":false},{"pmid":"21072044","id":"PMC_21072044","title":"The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors.","date":"2010","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/21072044","citation_count":33,"is_preprint":false},{"pmid":"22394247","id":"PMC_22394247","title":"Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.","date":"2012","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/22394247","citation_count":33,"is_preprint":false},{"pmid":"27779255","id":"PMC_27779255","title":"LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27779255","citation_count":30,"is_preprint":false},{"pmid":"27880729","id":"PMC_27880729","title":"LMO2 promotes tumor cell invasion and metastasis in basal-type breast cancer by altering actin cytoskeleton remodeling.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27880729","citation_count":30,"is_preprint":false},{"pmid":"21057528","id":"PMC_21057528","title":"A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21057528","citation_count":30,"is_preprint":false},{"pmid":"25203428","id":"PMC_25203428","title":"Diagnostic Utility of the Germinal Center-associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms.","date":"2015","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/25203428","citation_count":30,"is_preprint":false},{"pmid":"22058201","id":"PMC_22058201","title":"Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements.","date":"2011","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/22058201","citation_count":29,"is_preprint":false},{"pmid":"21459790","id":"PMC_21459790","title":"LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.","date":"2011","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/21459790","citation_count":29,"is_preprint":false},{"pmid":"16616188","id":"PMC_16616188","title":"Identification of the key LMO2-binding determinants on Ldb1.","date":"2006","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16616188","citation_count":29,"is_preprint":false},{"pmid":"24571259","id":"PMC_24571259","title":"LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.","date":"2014","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/24571259","citation_count":28,"is_preprint":false},{"pmid":"19141387","id":"PMC_19141387","title":"The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities.","date":"2009","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19141387","citation_count":28,"is_preprint":false},{"pmid":"26764384","id":"PMC_26764384","title":"The LMO2 oncogene regulates DNA replication in hematopoietic cells.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26764384","citation_count":27,"is_preprint":false},{"pmid":"18627109","id":"PMC_18627109","title":"Functional characterization of Lmo2-Cre transgenic zebrafish.","date":"2008","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/18627109","citation_count":26,"is_preprint":false},{"pmid":"21427293","id":"PMC_21427293","title":"Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21427293","citation_count":25,"is_preprint":false},{"pmid":"12609830","id":"PMC_12609830","title":"A PAR domain transcription factor is involved in the expression from a hematopoietic-specific promoter for the human LMO2 gene.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12609830","citation_count":25,"is_preprint":false},{"pmid":"30679322","id":"PMC_30679322","title":"ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms.","date":"2019","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/30679322","citation_count":24,"is_preprint":false},{"pmid":"28288039","id":"PMC_28288039","title":"LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.","date":"2017","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28288039","citation_count":24,"is_preprint":false},{"pmid":"17910069","id":"PMC_17910069","title":"Assembly of the oncogenic DNA-binding complex LMO2-Ldb1-TAL1-E12.","date":"2008","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/17910069","citation_count":24,"is_preprint":false},{"pmid":"26796495","id":"PMC_26796495","title":"LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma.","date":"2016","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26796495","citation_count":23,"is_preprint":false},{"pmid":"28775072","id":"PMC_28775072","title":"Lmo2 (LIM-Domain-Only 2) Modulates Sphk1 (Sphingosine Kinase) and Promotes Endothelial Cell Migration.","date":"2017","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28775072","citation_count":23,"is_preprint":false},{"pmid":"9209374","id":"PMC_9209374","title":"LIM-only protein Lmo2 forms a protein complex with erythroid transcription factor GATA-1.","date":"1997","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9209374","citation_count":23,"is_preprint":false},{"pmid":"22792348","id":"PMC_22792348","title":"Angiopoietin-2 is a direct transcriptional target of TAL1, LYL1 and LMO2 in endothelial cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22792348","citation_count":22,"is_preprint":false},{"pmid":"31366618","id":"PMC_31366618","title":"LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31366618","citation_count":21,"is_preprint":false},{"pmid":"16011889","id":"PMC_16011889","title":"SCL, GATA-2 and Lmo2 expression in neurogenesis.","date":"2005","source":"International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16011889","citation_count":21,"is_preprint":false},{"pmid":"7731680","id":"PMC_7731680","title":"Functional diversity of LIM proteins: amino-terminal activation domains in the oncogenic proteins RBTN1 and RBTN2.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7731680","citation_count":20,"is_preprint":false},{"pmid":"28973433","id":"PMC_28973433","title":"LMO2 is required for TAL1 DNA binding activity and initiation of definitive haematopoiesis at the haemangioblast stage.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/28973433","citation_count":20,"is_preprint":false},{"pmid":"21502424","id":"PMC_21502424","title":"The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow.","date":"2011","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21502424","citation_count":20,"is_preprint":false},{"pmid":"24252253","id":"PMC_24252253","title":"TTG2-regulated development is related to expression of putative AUXIN RESPONSE FACTOR genes in tobacco.","date":"2013","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/24252253","citation_count":19,"is_preprint":false},{"pmid":"22797922","id":"PMC_22797922","title":"Tobacco TTG2 suppresses resistance to pathogens by sequestering NPR1 from the nucleus.","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22797922","citation_count":19,"is_preprint":false},{"pmid":"25283843","id":"PMC_25283843","title":"Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice.","date":"2014","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/25283843","citation_count":19,"is_preprint":false},{"pmid":"15911088","id":"PMC_15911088","title":"Transcriptional control of fetal liver hematopoiesis: dominant negative effect of the overexpression of the LIM domain mutants of LMO2.","date":"2005","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/15911088","citation_count":19,"is_preprint":false},{"pmid":"33156841","id":"PMC_33156841","title":"TOP1α, UPF1, and TTG2 regulate seed size in a parental dosage-dependent manner.","date":"2020","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/33156841","citation_count":18,"is_preprint":false},{"pmid":"33503448","id":"PMC_33503448","title":"LMO2 upregulation due to AR deactivation in cancer-associated fibroblasts induces non-cell-autonomous growth of prostate cancer after androgen deprivation.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/33503448","citation_count":18,"is_preprint":false},{"pmid":"27255279","id":"PMC_27255279","title":"Tobacco TTG2 regulates vegetative growth and seed production via the predominant role of ARF8 in cooperation with ARF17 and ARF19.","date":"2016","source":"BMC plant biology","url":"https://pubmed.ncbi.nlm.nih.gov/27255279","citation_count":17,"is_preprint":false},{"pmid":"34330825","id":"PMC_34330825","title":"Fli1+ cells transcriptional analysis reveals an Lmo2-Prdm16 axis in angiogenesis.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34330825","citation_count":17,"is_preprint":false},{"pmid":"36044573","id":"PMC_36044573","title":"Endothelial versus pronephron fate decision is modulated by the transcription factors Cloche/Npas4l, Tal1, and Lmo2.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36044573","citation_count":17,"is_preprint":false},{"pmid":"25769544","id":"PMC_25769544","title":"BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.","date":"2015","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/25769544","citation_count":16,"is_preprint":false},{"pmid":"34382935","id":"PMC_34382935","title":"LMO2 is essential to maintain the ability of progenitors to differentiate into T-cell lineage in mice.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34382935","citation_count":16,"is_preprint":false},{"pmid":"24407558","id":"PMC_24407558","title":"Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex.","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24407558","citation_count":16,"is_preprint":false},{"pmid":"28594133","id":"PMC_28594133","title":"Diagnostic value of STMN1, LMO2, HGAL, AID expression and 1p36 chromosomal abnormalities in primary cutaneous B cell lymphomas.","date":"2017","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/28594133","citation_count":16,"is_preprint":false},{"pmid":"29778661","id":"PMC_29778661","title":"Epigenetic dysregulation of ZEB1 is involved in LMO2-promoted T-cell acute lymphoblastic leukaemia leukaemogenesis.","date":"2018","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29778661","citation_count":16,"is_preprint":false},{"pmid":"1281693","id":"PMC_1281693","title":"Rhom-2 expression does not always correlate with abnormalities on chromosome 11 at band p13 in T-cell acute lymphoblastic leukemia.","date":"1992","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1281693","citation_count":16,"is_preprint":false},{"pmid":"8035604","id":"PMC_8035604","title":"Simultaneous expression of RBTN-2 and BCR-ABL oncogenes in a T-ALL with a t(11;14)(p13;q11) and a late-appearing Philadelphia chromosome.","date":"1994","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8035604","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49320,"output_tokens":10365,"usd":0.151718,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20821,"output_tokens":5408,"usd":0.119652,"stage2_stop_reason":"end_turn"},"total_usd":0.27137,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"LMO2 acts as a bridging molecule in erythroid cells, forming a pentameric DNA-binding complex with TAL1, E47 (E2A), GATA-1, and LDB1/NLI that binds a bipartite DNA motif comprising an E-box (CAGGTG) followed ~9 bp downstream by a GATA site; in vivo assembly requires all five proteins and the complex functions as a transcriptional transactivator.\",\n      \"method\": \"Co-immunoprecipitation, gel-shift/EMSA (CASTing), mammalian two-hybrid, reporter transactivation assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (Co-IP, EMSA, two-hybrid, reporter assay) in a single rigorous study establishing both the complex composition and DNA-binding specificity; replicated by companion papers\",\n      \"pmids\": [\"9214632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"LMO2 (RBTN2) is a nuclear protein expressed in the erythroid lineage; homozygous knockout in mice causes complete failure of yolk sac erythropoiesis and embryonic lethality (~E10.5), demonstrating an essential role in erythroid lineage specification.\",\n      \"method\": \"Homologous recombination knockout in mice, in vitro yolk sac differentiation, double-mutant ES cell differentiation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic loss-of-function with defined cellular phenotype, replicated across multiple experimental systems in one study\",\n      \"pmids\": [\"8033210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"LMO2 (RBTN2) protein is not phosphorylated and forms a stable complex with the phosphoprotein TAL1 in the nucleus of erythroid cells; a similar RBTN1–TAL1 complex occurs in a T-cell leukemia line.\",\n      \"method\": \"Co-immunoprecipitation with anti-RBTN2 and anti-TAL1 antisera from nuclear extracts\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP from endogenous nuclear proteins in erythroid cells; independently consistent with multiple follow-up studies\",\n      \"pmids\": [\"8078932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"LMO2 (RBTN2) directly interacts in vivo and in vitro with GATA1 and GATA2 zinc-finger transcription factors, as well as with TAL1; a quaternary complex of RBTN2, TAL1, GATA1, and E47 can be demonstrated by mammalian two-hybrid analysis.\",\n      \"method\": \"In vitro GST pulldown, in vivo co-immunoprecipitation, mammalian two-hybrid assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro and in vivo binding confirmed by multiple methods; replicated in companion papers\",\n      \"pmids\": [\"7568177\", \"9209374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"LMO2 and TAL1 form protein dimers specifically in thymocytes of double-transgenic mice (not in single transgenics); co-expression of Lmo2 and Tal1 in T cells causes near-complete thymic repopulation by immature T cells from birth and accelerates T-cell tumor development by ~3 months compared to Lmo2 transgene alone, demonstrating oncogenic synergy through protein interaction.\",\n      \"method\": \"Transgenic mouse double-mutant analysis, co-immunoprecipitation from thymocytes, thymic phenotyping\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (double transgenic) combined with direct protein interaction evidence and defined cellular phenotype\",\n      \"pmids\": [\"8605871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"LMO2-null ES cells do not contribute to any hematopoietic lineage in adult chimeric mice, demonstrating LMO2 is required for all stages of adult hematopoiesis; re-introduction of an LMO2 expression vector rescues contribution to all lineages, confirming the requirement is cell-autonomous.\",\n      \"method\": \"ES cell chimera analysis, retroviral rescue experiment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rigorous loss-of-function plus gain-of-function rescue in vivo with defined lineage phenotype\",\n      \"pmids\": [\"9520463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"LDB1 and LMO2 form a stable endogenous complex in erythroid cells; LDB1 and LMO2 together with SCL/E12 can assemble on SCL-binding DNA sites; forced overexpression of either LDB1 or LMO2 in proerythroblasts inhibits erythroid differentiation, indicating the LDB1/LMO2 complex maintains erythroid precursors in an immature state.\",\n      \"method\": \"Co-immunoprecipitation from MEL cells, EMSA, forced overexpression in G1ER proerythroblast cells with differentiation readout\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — endogenous complex confirmed by Co-IP, DNA binding shown by EMSA, and functional consequence demonstrated by OE experiment with cellular differentiation readout\",\n      \"pmids\": [\"9391090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"In Lmo2-transgenic T cells, LMO2 forms an oligomeric DNA-binding complex that recognizes a bipartite motif of two E-box sequences ~10 bp apart (distinct from the erythroid complex), specifically in immature CD4−CD8− (double-negative) thymocytes and in T-cell tumors.\",\n      \"method\": \"EMSA (CASTing), band-shift assays, cell sorting of thymocyte subsets\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CASTing and EMSA with defined cell-type specificity; mechanistically distinguishes T-cell from erythroid LMO2 complex\",\n      \"pmids\": [\"9707419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Lmo2-null ES cells contribute normally to the capillary network until E9, but thereafter fail to contribute to endothelial cells of large vessel walls; Lmo2 is not required for de novo vasculogenesis but is necessary for angiogenic remodeling of the existing capillary network into mature vasculature.\",\n      \"method\": \"Chimeric mouse analysis using Lmo2-null ES cells, histological and endothelial marker analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic loss-of-function in chimeras with stage-specific, lineage-specific phenotypic dissection\",\n      \"pmids\": [\"10618416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"LMO2, together with TAL1 and E47, upregulates VE-cadherin transcription in endothelial cells; knockdown of LMO2 (or TAL1, E47) reduces VE-cadherin mRNA and protein; ectopic co-expression of TAL1, E47, and LMO2 activates VE-cadherin transcription in non-endothelial cells; TAL1, E47, and LMO2 occupy the VE-cadherin promoter at an E-box/GATA motif in HUVECs.\",\n      \"method\": \"siRNA knockdown, reporter assay, ectopic overexpression, chromatin immunoprecipitation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (KD, OE, ChIP, reporter) establish direct transcriptional regulation of VE-cadherin by the LMO2 complex\",\n      \"pmids\": [\"17242194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SCL (TAL1) is the predominant interaction partner of LMO2 in hematopoietic cells; the interaction occurs through the loop and helix-2 region of SCL; this interaction nucleates assembly of SCL complexes on DNA, is required for target gene induction and erythroid/megakaryocytic differentiation; furthermore, interaction with SCL prevents LMO2 degradation by the proteasome, thus stabilizing LMO2 protein levels.\",\n      \"method\": \"Co-immunoprecipitation, mutagenesis of SCL interaction interface, reporter/target gene induction assays, proteasome inhibitor experiments, protein stability assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mutagenesis of binding interface combined with protein stability assays and functional readouts; multiple orthogonal methods in single study\",\n      \"pmids\": [\"17878155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Crystal structure of LMO2 in complex with the LID domain of LDB1 at 2.4 Å resolution shows LMO2 is largely unstructured and kept in register by LID binding both LIM domains; large conformational movements around a conserved hinge between the LIM domains are observed; this conformational flexibility is necessary for binding of LMO2 to SCL/TAL1 in vitro and for complex function in vivo.\",\n      \"method\": \"X-ray crystallography, in vitro binding assay, in vivo functional rescue assay, molecular docking\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure at 2.4 Å plus mutagenesis/flexibility validated by in vitro binding and in vivo function in a single rigorous study\",\n      \"pmids\": [\"21076045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Crystal structure of the (SCL:E47)bHLH:LMO2:LDB1LID complex bound to DNA reveals that LMO2, upon binding SCL, induces new hydrogen bonds within the SCL:E47 heterodimer strengthening it, while imposing a rotation on E47 that weakens E47:DNA contact, shifting main DNA-binding activity to additional partners; this provides the structural basis for LMO2-driven recruitment of the SCL:E47 heterodimer to hematopoietic targets.\",\n      \"method\": \"X-ray crystallography of pentameric complex, biochemical binding analyses\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure of intact DNA-bound complex combined with biochemical validation; defines molecular mechanism at atomic resolution\",\n      \"pmids\": [\"23831025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LMO2 induces self-renewal of committed CD4−CD8− thymocytes more than 8 months before overt T-ALL development; these self-renewing thymocytes retain T-cell differentiation capacity but express HSC-typical genes; forced expression of HHEX (one such gene) is sufficient to initiate thymocyte self-renewal in vivo, identifying HHEX as a key downstream effector of Lmo2-induced self-renewal.\",\n      \"method\": \"Conditional cell fate mapping (lineage tracing), transgenic mouse model, retroviral overexpression of Hhex\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic cell fate mapping plus functional downstream gene validation in vivo; defines mechanism of oncogenic action\",\n      \"pmids\": [\"20093438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The N-terminal finger of GATA1 simultaneously binds both FOG1 and LMO2; LMO2 in turn can simultaneously contact both GATA1 and SCL/TAL1 at bipartite E-box/WGATAR sites; structural data show FOG1 and TAL1/E2A/LMO2/LDB1 can co-occupy GATA1-dependent gene regulatory elements.\",\n      \"method\": \"NMR/structural analysis, binding assays, peptide competition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural data revealing simultaneous binding of two partners to GATA1 N-finger, single study with multiple structural/biochemical validations\",\n      \"pmids\": [\"21844373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LMO2 is recruited to DNA replication origins by direct interaction with three replication enzymes—DNA polymerase delta (POLD1), DNA primase (PRIM1), and MCM6—and tethering LMO2 to synthetic sequences is sufficient to transform them into replication origins; lowering LMO2 in erythroid progenitors delays G1-S and arrests growth, while ectopic expression in thymocytes drives DNA replication and cell cycle entry.\",\n      \"method\": \"Co-immunoprecipitation, replication origin-tethering assay, shRNA knockdown with cell cycle analysis, BrdU incorporation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP identifies replication enzyme partners, synthetic origin assay demonstrates sufficiency, loss- and gain-of-function with defined cell cycle phenotypes; multiple orthogonal methods\",\n      \"pmids\": [\"26764384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LMO2 interacts with 53BP1 during DNA double-strand break repair and thereby inhibits BRCA1 recruitment to DSBs, causing functional homologous recombination deficiency; LMO2-positive DLBCL and T-ALL cells display sensitivity to PARP inhibitors comparable to BRCA1-deficient cells.\",\n      \"method\": \"Co-immunoprecipitation (LMO2–53BP1 interaction), HR repair assays, PARP inhibitor sensitivity assays, BRCA1 recruitment foci\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct protein interaction plus functional HR assay and pharmacological sensitivity readout; multiple orthogonal methods establishing a new mechanistic role\",\n      \"pmids\": [\"31447348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LMO2 is deacetylated on lysine residues K74 and K78 via the NAMPT/SIRT2 pathway; deacetylation is required for LMO2 to interact with LDB1 and activate the TAL1 transcriptional complex; NAMPT or SIRT2 inhibition suppresses in vitro growth and in vivo engraftment of T-ALL cells by diminishing LMO2 deacetylation.\",\n      \"method\": \"Mass spectrometry identification of acetylation sites, mutagenesis of K74/K78, Co-IP of LMO2–LDB1 interaction, NAMPT/SIRT2 inhibitor treatment, mouse engraftment assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — PTM site identified by MS and confirmed by mutagenesis, writer/eraser defined (SIRT2), functional consequence on complex assembly and cellular phenotype demonstrated\",\n      \"pmids\": [\"31366618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Crystal structure of LMO2 bound to an inhibitory single-domain antibody fragment reveals a conformational change (bending at the central helical hinge between the two LIM domains) compared to the LDB1-bound form; this structural contortion sequesters LMO2 in a non-functional state, suggesting that LMO2 is intrinsically disordered when newly synthesized and adopts its active conformation upon binding a partner protein.\",\n      \"method\": \"X-ray crystallography, single-domain antibody inhibition assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure plus functional inhibition assay; single study with structural and functional validation\",\n      \"pmids\": [\"24407558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Both LIM domains of LMO2 are required for high-affinity binding to LDB1 (Kd ~20 nM); the first LIM domain primarily mediates this interaction while the second increases affinity ~10-fold; LMO2 binds LDB1 with ~2-fold lower affinity than does LMO4, implying that elevated LMO2 levels rather than intrinsically higher affinity drive LDB1 sequestration in leukemia.\",\n      \"method\": \"ELISA-based binding assay, protein engineering, mutagenesis, yeast two-hybrid analysis, phage display\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — quantitative binding affinities measured by ELISA, validated by mutagenesis and yeast two-hybrid; multiple orthogonal methods\",\n      \"pmids\": [\"16616188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Human BEX2 specifically interacts with LMO2 (confirmed by GST pulldown and Co-IP) and is part of a DNA-binding complex with LMO2 as demonstrated by EMSA; BEX2 enhances LMO2 transcriptional activity in vivo; a neuronal bHLH protein NSCL2 was identified as an additional LMO2-binding partner, and LMO2 upregulates NSCL2-dependent transcription, augmented by BEX2.\",\n      \"method\": \"GST pulldown, co-immunoprecipitation, EMSA, mammalian two-hybrid, reporter assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple binding methods (pulldown + Co-IP + EMSA) and functional reporter assay in single lab study\",\n      \"pmids\": [\"16314316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"An anti-LMO2 single-chain Fv antibody binds LMO2 through its third and fourth LIM finger structures (LIM2 domain); intracellular expression inhibits Lmo2-dependent erythropoiesis but not endothelial development; it also inhibits Lmo2-dependent leukemia in a mouse T-cell tumor transplantation assay.\",\n      \"method\": \"Intracellular antibody capture technology, vector-mediated intracellular expression, erythropoiesis assay, mouse tumor transplantation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional inhibition by specific intracellular antibody with defined binding site, two distinct functional readouts; single lab\",\n      \"pmids\": [\"18438427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Lmo2 requires Lyl1 (not Scl/Tal1) to mediate its leukemic functions in the thymus; Lyl1 deletion in Lmo2-transgenic mice abolishes all oncogenic functions including HSC-like gene signature upregulation, thymocyte self-renewal, and T-ALL development; Scl deletion has no effect. LMO2 and LYL1 are co-expressed in ETP-ALL patient samples and LYL1 is required for growth of ETP-ALL cell lines.\",\n      \"method\": \"Conditional double-knockout transgenic mouse model (Lmo2-Tg × Scl-cKO or Lyl1-cKO), shRNA knockdown of LYL1 in human cell lines, gene expression profiling\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in mice with defined phenotype plus human cell line validation; demonstrates obligate partner specificity\",\n      \"pmids\": [\"23926305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Conditional knockout of Lmo2 using Rag1-, CD19-, or Lck-Cre drivers causes efficient Lmo2 deletion in early lymphoid progenitors but produces no disturbance of T- or B-cell lymphopoiesis, establishing that LMO2 has no mandatory role in normal T- or B-cell development.\",\n      \"method\": \"Conditional knockout mice (loxP/Cre system), flow cytometry of lymphoid populations\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean conditional KO with efficient deletion confirmed; negative result is mechanistically informative and clearly established\",\n      \"pmids\": [\"14645513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TAL1's DNA-binding activity is not required for cooperation with LMO2 in T-cell leukemia; Tal1/Lmo2 and MutTAL1/Lmo2 bitransgenic mice develop leukemia with identical kinetics; both reduce E47/HEB transcriptional activity, suggesting LMO2 cooperates with TAL1 to interfere with E47/HEB transcriptional functions rather than to activate target genes directly.\",\n      \"method\": \"Double-transgenic mouse model with DNA-binding mutant TAL1, leukemia onset comparison, E47/HEB reporter assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in mice with mechanistic reporter assays; single lab, single study\",\n      \"pmids\": [\"21057528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The NH2-terminal regions of RBTN1 and RBTN2 (LMO2) are capable of supporting transcriptional transactivation; using Isl-1 homeodomain fusions and yeast assays, the first 27 amino acids of RBTN2 are sufficient for transactivation, and RBTN2 forms homodimers in yeast.\",\n      \"method\": \"Reporter transfection assay, yeast two-hybrid assay, Isl-1 homeodomain fusion constructs\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter and yeast two-hybrid assays; single lab, defines N-terminal transactivation domain and homodimerization\",\n      \"pmids\": [\"7731680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"LMO2 LIM2 domain deletion abolishes binding to GATA proteins (while LIM1 deletion does not); overexpression of LMO2 with mutant LIM2 but intact LIM1 causes dominant-negative inhibition of fetal hematopoiesis in transgenic mice (fetal death, small livers, decreased hematopoiesis) and inhibits DMSO-induced erythroid differentiation in MEL cells.\",\n      \"method\": \"Co-immunoprecipitation with LIM-domain deletion/mutation constructs, transgenic mouse hematopoiesis analysis, MEL cell differentiation assay\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain mapping by Co-IP combined with in vivo and in vitro dominant-negative phenotype; single lab\",\n      \"pmids\": [\"15911088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"LMO2 is required at the haemangioblast stage to position the TAL1/LMO2/LDB1 complex to regulatory elements important for establishing the haematopoietic developmental program; in the absence of LMO2, TAL1 target-site recognition genome-wide is impaired; TAL1 also sustains Lmo2 expression at this stage.\",\n      \"method\": \"Lmo2−/− ES cell differentiation to haemangioblasts, ChIP-seq (TAL1, LMO2, LDB1), genome-wide gene expression analysis, comparison with Tal1−/− cells\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq in defined loss-of-function cells revealing stage-specific cistrome requirements; multiple orthogonal genomics methods\",\n      \"pmids\": [\"28973433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GATA2 and LMO2 form transcriptional complexes in endothelial cells and directly regulate neuropilin-2 (NRP2) gene expression; knockdown of either GATA2 or LMO2 inhibits VEGF-induced angiogenesis and NRP2 promoter activity; NRP2 overexpression partially rescues the knockdown phenotype.\",\n      \"method\": \"siRNA knockdown, promoter reporter assay, ChIP, angiogenesis sprouting assay, rescue by NRP2 overexpression\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter plus rescue demonstrate direct transcriptional regulation; single lab\",\n      \"pmids\": [\"23892628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Angiopoietin-2 (ANG-2) is a direct transcriptional target of LMO2, TAL1, LYL1, and GATA2 in endothelial cells; LMO2 assembles TAL1-E47, LYL1-LYL1, and/or LYL1-TAL1 dimers with GATA2 at a conserved Ebox-GATA composite element in the ANG-2 promoter; ChIP confirms occupancy of this element.\",\n      \"method\": \"siRNA knockdown, ChIP, reporter assay, ectopic co-expression in non-endothelial cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (KD, ChIP, reporter, OE) establish direct regulation; single lab\",\n      \"pmids\": [\"22792348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"c-Myb directly binds the LMO2 promoter and transactivates LMO2 expression; LMO2 (along with KLF1) overexpression partially rescues the erythroid differentiation defect caused by c-Myb silencing in human CD34+ cells.\",\n      \"method\": \"Chromatin immunoprecipitation, luciferase reporter assay, retroviral overexpression rescue, c-Myb siRNA knockdown\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter establishes direct transcriptional regulation; rescue experiment confirms functional relevance; single lab\",\n      \"pmids\": [\"20686118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Lmo2 directly regulates Sphk1 (sphingosine kinase 1) gene expression in endothelial cells by binding the Sphk1 promoter (shown by ChIP-PCR); Lmo2 KD reduces Sphk1 expression; Sphk1 mRNA rescues impaired intersegmental vessel formation and endothelial cell migration in Lmo2-KD zebrafish and human cells.\",\n      \"method\": \"Morpholino knockdown in zebrafish, siRNA in HUVECs, ChIP-PCR, scratch migration assay, mRNA rescue\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-PCR demonstrates direct promoter binding, KD and rescue confirm functional epistasis; single lab with in vivo and in vitro methods\",\n      \"pmids\": [\"28775072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Lmo2 directly binds the promoter of prdm16 in endothelial cells (shown by ChIP-PCR); lmo2 loss-of-function zebrafish mutants show reduced prdm16 expression and impaired angiogenesis; Prdm16 KD phenocopies lmo2 mutant vascular defects, defining an Lmo2–Prdm16 axis in angiogenesis.\",\n      \"method\": \"ChIP-PCR, lmo2 loss-of-function zebrafish mutants, morpholino KD, endothelial cell differentiation/migration assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-PCR plus loss-of-function genetics; single lab but in vivo and in vitro methods\",\n      \"pmids\": [\"34330825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In basal-type breast cancer cells, LMO2 localizes predominantly to the cytoplasm and interacts with cofilin-1, a regulator of actin cytoskeleton dynamics; this interaction promotes tumor cell migration, invasion, and metastasis in vivo.\",\n      \"method\": \"Co-immunoprecipitation (LMO2–cofilin1), subcellular fractionation/immunofluorescence, migration/invasion assays, SCID mouse metastasis model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP plus localization plus functional cellular assays; single lab, but multiple orthogonal readouts\",\n      \"pmids\": [\"27880729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In breast and colorectal cancer cells, LMO2 localizes to the cytoplasm and binds to the PDZ domain of Dishevelled-1/2 (DVL-1/2); this interaction attenuates canonical Wnt/β-catenin signaling; LMO2 downregulation increases cell proliferation and reduces apoptosis in these cells.\",\n      \"method\": \"Co-immunoprecipitation (LMO2–DVL1/2), β-catenin activity assay, LMO2 overexpression and knockdown with proliferation/apoptosis readouts\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP identifies cytoplasmic interaction partner; functional assays show pathway consequence; single lab\",\n      \"pmids\": [\"27779255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LMO2 recruits SAP18 and HDAC1 to form an epigenetic regulatory complex on the ZEB1 promoter, inducing histone deacetylation and transcriptional repression of ZEB1; ZEB1 downregulation increases leukemia stem cell phenotype and reduces sensitivity to methotrexate in T-ALL; HDAC inhibitor TSA restores chemosensitivity.\",\n      \"method\": \"Co-immunoprecipitation (LMO2–SAP18–HDAC1), ChIP at ZEB1 promoter, HDAC inhibitor treatment, shRNA knockdown, leukemia stem cell assays\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP establishes complex, ChIP confirms promoter occupancy, pharmacological rescue links HDAC activity to phenotype; single lab\",\n      \"pmids\": [\"29778661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LMO2 directly binds the Bcl11a and Tcf7 loci in pro-B cells; LMO2 is required to maintain T-lineage potential in pre-thymic progenitors; CRISPR/Cas9 deletion of Lmo2 abolishes T-lineage potential; ectopic Lmo2 expression restores this potential by enabling Bcl11a and Tcf7 expression.\",\n      \"method\": \"CRISPR/Cas9 knockout, ChIP (LMO2 at Bcl11a and Tcf7 loci), ectopic expression rescue, in vitro T-cell differentiation assay\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP identifies direct target loci, CRISPR KO and rescue confirm functional requirement; single lab\",\n      \"pmids\": [\"34382935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"HHEX is a direct transcriptional target of LMO2 in T-ALL; conditional inactivation of Hhex in CD2-Lmo2 transgenic mice markedly attenuates T-ALL development, establishing HHEX as a crucial mediator of Lmo2's oncogenic function.\",\n      \"method\": \"ChIP (LMO2 at HHEX locus), conditional Hhex knockout in Lmo2-transgenic mice, T-ALL incidence analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus conditional genetic epistasis demonstrate direct transcriptional target and functional requirement; single lab\",\n      \"pmids\": [\"24465765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"miR-223 binds the 3' UTR of LMO2 and reduces LMO2 mRNA and protein levels; enforced expression of miR-223 impairs erythroid differentiation, phenocopied by LMO2 siRNA knockdown; the decline of miR-223 during erythropoiesis is required to allow LMO2 upregulation and erythroid commitment.\",\n      \"method\": \"3' UTR luciferase reporter assay, miR-223 overexpression, LMO2 siRNA knockdown, erythroid colony assay\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct 3' UTR binding validated by reporter, loss-of-function of LMO2 phenocopies miRNA OE; single lab\",\n      \"pmids\": [\"19278969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The LMO2 proximal promoter is active in hematopoietic progenitor and endothelial cell lines in a manner dependent on three conserved ETS-binding sites bound in vivo by ELF1, FLI1, and ETS1; transgenic analysis confirms the proximal promoter drives expression in endothelial cells in vivo but additional enhancers are needed for hematopoietic expression.\",\n      \"method\": \"Comparative genomics, transient and stable transfections, ChIP, transgenic mouse analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms in vivo factor binding to LMO2 promoter, transgenic mice validate tissue specificity; single lab\",\n      \"pmids\": [\"15994290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LMO2 is identified as an AR (androgen receptor) target gene in prostate fibroblasts; AR directly represses LMO2 through binding to androgen response elements (AREs) in the LMO2 locus (ChIP-seq); upon AR deactivation, LMO2 overexpression in fibroblasts promotes castration-resistant PCa cell growth non-cell-autonomously via paracrine IL-11 and FGF-9.\",\n      \"method\": \"ChIP-seq (AR binding at LMO2 locus), LMO2 knockdown and overexpression, paracrine co-culture experiments, cytokine neutralization\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq establishes direct AR repression, functional non-cell-autonomous signaling confirmed by co-culture and paracrine factor experiments; single lab\",\n      \"pmids\": [\"33503448\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LMO2 is a LIM-only scaffold protein that functions as an obligatory bridging component of multiprotein transcriptional complexes—most prominently a pentameric complex containing TAL1/SCL, E47, GATA-1, and LDB1 that binds bipartite E-box/GATA DNA motifs—where its conformational flexibility enables partner-induced structural ordering; SCL interaction stabilizes LMO2 from proteasomal degradation; deacetylation on K74/K78 by SIRT2 (via NAMPT) is required for LDB1 engagement; the complex directly activates erythroid, endothelial, and hematopoietic stem-cell target genes (including VE-cadherin, ANG-2, HHEX, Sphk1, Prdm16, Bcl11a, and Tcf7), while LMO2 also interfaces with DNA replication machinery (POLD1, PRIM1, MCM6) to promote S-phase entry, and in certain solid-tumor contexts localizes to the cytoplasm where it interacts with DVL-1/2 (attenuating Wnt/β-catenin) or cofilin-1 (promoting cytoskeletal remodeling), and in DLBCL interacts with 53BP1 to block BRCA1 recruitment and impair homologous recombination repair.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"LMO2 is a nuclear LIM-only protein that functions as an obligatory bridging scaffold within multiprotein transcription complexes governing erythroid, endothelial, and hematopoietic stem-cell programs [#0, #1]. In erythroid cells it nucleates a pentameric DNA-binding complex with TAL1/SCL, E47/E2A, GATA-1, and LDB1/NLI that recognizes a bipartite E-box/GATA composite motif and transactivates target genes [#0, #3], and it likewise bridges GATA1 simultaneously with TAL1/E2A at GATA-dependent regulatory elements [#14]. Structurally, LMO2 is intrinsically disordered when newly synthesized and acquires its active conformation upon partner binding: the LID domain of LDB1 holds both LIM domains in register through a flexible hinge, and this conformational plasticity is required for SCL/TAL1 engagement and complex function [#11, #18, #19]. Binding of SCL strengthens the SCL:E47 heterodimer while shifting DNA contact to partner factors, defining the atomic basis for complex recruitment to hematopoietic targets [#12], and SCL interaction additionally protects LMO2 from proteasomal degradation [#10]. Deacetylation of LMO2 on K74/K78 by the NAMPT/SIRT2 pathway is required for LDB1 engagement and complex activation [#17]. Through this complex LMO2 directly activates target genes including VE-cadherin, NRP2, ANG-2, Sphk1, Prdm16, Bcl11a, and Tcf7 to drive endothelial remodeling, hematopoietic specification, and lymphoid lineage potential [#9, #28, #29, #31, #32, #36], and is genetically essential for yolk-sac erythropoiesis, all adult hematopoiesis, and angiogenic vascular remodeling [#1, #5, #8]. LMO2 is a potent oncogene: ectopic expression drives self-renewal of immature thymocytes and T-ALL through downstream effectors HHEX and the obligate partner LYL1 (rather than SCL) [#13, #22, #37]. Beyond transcription, LMO2 is recruited to DNA replication origins via POLD1, PRIM1, and MCM6 to promote S-phase entry [#15], and in DLBCL it interacts with 53BP1 to block BRCA1 recruitment, conferring homologous-recombination deficiency and PARP-inhibitor sensitivity [#16]. In solid-tumor contexts LMO2 can localize to the cytoplasm, where it binds cofilin-1 to promote migration and invasion, or DVL-1/2 to attenuate Wnt/β-catenin signaling [#33, #34].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established LMO2 as a nuclear erythroid-lineage protein with a non-redundant developmental requirement, defining its biological importance before its molecular activity was known.\",\n      \"evidence\": \"Homozygous knockout in mice with in vitro yolk-sac differentiation; reciprocal Co-IP of endogenous nuclear proteins\",\n      \"pmids\": [\"8033210\", \"8078932\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the molecular mechanism by which LMO2 acts\", \"Embryonic lethality precluded analysis of adult and other lineages\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identified the partner network by showing LMO2 binds GATA1/GATA2 and TAL1 and can form a quaternary complex with E47, establishing LMO2 as a multivalent protein-interaction hub.\",\n      \"evidence\": \"GST pulldown, in vivo Co-IP, and mammalian two-hybrid; plus reporter and yeast assays defining an N-terminal transactivation region and homodimerization\",\n      \"pmids\": [\"7568177\", \"9209374\", \"7731680\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish DNA-binding specificity of the assembled complex\", \"N-terminal transactivation function not validated in the native complex context\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Defined the core erythroid mechanism: LMO2 bridges a pentameric TAL1/E47/GATA-1/LDB1 complex onto a bipartite E-box/GATA motif to transactivate transcription, resolving how the partners cooperate on DNA.\",\n      \"evidence\": \"Co-IP, EMSA/CASTing, mammalian two-hybrid, reporter transactivation; endogenous LDB1–LMO2 complex with overexpression differentiation readout\",\n      \"pmids\": [\"9214632\", \"9391090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not reveal the structural basis of assembly\", \"Direct endogenous target genes not yet identified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed LMO2 is cell-autonomously required for all adult hematopoietic lineages and, separately, that an oligomeric LMO2 complex recognizing a distinct double-E-box motif forms in immature thymocytes, distinguishing physiological from leukemic complexes.\",\n      \"evidence\": \"ES-cell chimera analysis with retroviral rescue; EMSA/CASTing with thymocyte subset sorting\",\n      \"pmids\": [\"9520463\", \"9707419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The composition of the thymic double-E-box complex was not fully resolved\", \"Did not identify downstream effectors of the leukemic complex\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Dissected the vascular role, establishing LMO2 is dispensable for vasculogenesis but required for angiogenic remodeling of the capillary network into mature vessels.\",\n      \"evidence\": \"Chimeric mouse analysis with Lmo2-null ES cells and endothelial marker histology\",\n      \"pmids\": [\"10618416\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the endothelial target genes mediating remodeling\", \"Mechanistic basis of the stage-specific requirement unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Quantified LMO2–LDB1 binding, showing both LIM domains contribute and that LMO2 binds with lower affinity than LMO4, implying leukemic LDB1 sequestration is driven by elevated LMO2 levels rather than higher intrinsic affinity.\",\n      \"evidence\": \"ELISA-based affinity measurement, protein engineering, mutagenesis, yeast two-hybrid, phage display\",\n      \"pmids\": [\"16616188\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address how affinity translates into in vivo complex selectivity\", \"Other LIM-domain partner affinities not compared\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified the first direct endothelial target and the central role of SCL, showing the LMO2/TAL1/E47 complex occupies and activates the VE-cadherin promoter and that SCL stabilizes LMO2 from proteasomal degradation.\",\n      \"evidence\": \"siRNA, ChIP, reporter and ectopic expression; mutagenesis of the SCL interface plus proteasome inhibition and protein-stability assays\",\n      \"pmids\": [\"17242194\", \"17878155\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the degradation machinery acting on free LMO2\", \"Generality of the stabilization mechanism across cell types not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Provided the structural and oncogenic mechanism: a 2.4 Å LMO2–LDB1 LID structure revealed LMO2 is largely unstructured and held in register by LID, with hinge flexibility required for SCL binding; in parallel, LMO2 was shown to drive thymocyte self-renewal through the downstream effector HHEX.\",\n      \"evidence\": \"X-ray crystallography with in vitro binding and in vivo rescue; lineage-tracing transgenic model with retroviral Hhex expression\",\n      \"pmids\": [\"21076045\", \"20093438\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the full DNA-bound complex not yet solved\", \"How HHEX maintains self-renewal mechanistically not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Resolved the atomic basis of target recruitment and the obligate leukemic partner, showing the DNA-bound (SCL:E47):LMO2:LDB1 structure where LMO2 reshapes the SCL:E47 heterodimer, and that Lyl1—not Scl—is required for Lmo2's leukemic functions.\",\n      \"evidence\": \"X-ray crystallography of the pentameric DNA-bound complex; conditional double-knockout mice with human ETP-ALL cell-line validation\",\n      \"pmids\": [\"23831025\", \"23926305\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why Lyl1 substitutes for Scl in leukemia at the structural level unresolved\", \"Cistrome differences between Scl- and Lyl1-containing complexes not mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Reinforced the conformational-switch model with a structure of LMO2 bent at the LIM hinge by an inhibitory antibody, and identified HHEX as a direct LMO2 target genetically required for T-ALL.\",\n      \"evidence\": \"X-ray crystallography with single-domain antibody inhibition; ChIP plus conditional Hhex knockout in Lmo2-transgenic mice\",\n      \"pmids\": [\"24407558\", \"24465765\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The native unbound conformation in cells not directly observed\", \"Full set of HHEX-dependent leukemic targets unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended LMO2 beyond transcription to DNA replication, showing direct binding to POLD1, PRIM1, and MCM6 recruits LMO2 to origins and is sufficient to convert synthetic sequences into replication origins driving S-phase entry.\",\n      \"evidence\": \"Co-IP, replication-origin tethering assay, shRNA with cell-cycle analysis, BrdU incorporation\",\n      \"pmids\": [\"26764384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How origin recruitment is coordinated with the transcriptional role unclear\", \"Whether DNA binding by the complex is required for origin function not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined LMO2's genome-wide cistrome role at the haemangioblast stage—positioning the TAL1/LMO2/LDB1 complex at hematopoietic regulatory elements—and identified a cytoplasmic, non-transcriptional function via cofilin-1 in invasive breast cancer.\",\n      \"evidence\": \"ChIP-seq in Lmo2-null haemangioblasts; Co-IP, fractionation, migration/invasion assays and a SCID metastasis model\",\n      \"pmids\": [\"28973433\", \"27880729\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Switch between nuclear scaffold and cytoplasmic cofilin functions not mechanistically defined\", \"Cofilin interaction validated in a single cancer context\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Uncovered post-translational and DNA-repair mechanisms: K74/K78 deacetylation by NAMPT/SIRT2 is required for LDB1 engagement and complex activation, and LMO2–53BP1 interaction blocks BRCA1 recruitment to confer HR deficiency and PARP-inhibitor sensitivity.\",\n      \"evidence\": \"Mass spectrometry, mutagenesis, Co-IP, NAMPT/SIRT2 inhibitor and engraftment assays; HR repair assays, BRCA1 foci and PARP-inhibitor sensitivity\",\n      \"pmids\": [\"31366618\", \"31447348\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The acetyltransferase that opposes SIRT2 on LMO2 not identified\", \"How nuclear LMO2 is partitioned between transcription and 53BP1-bound DSBs unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected LMO2 to lineage-decision and angiogenic target genes, showing direct binding to Bcl11a/Tcf7 to maintain T-lineage potential and to prdm16 in endothelial angiogenesis, alongside an AR-repressed paracrine role in prostate cancer.\",\n      \"evidence\": \"CRISPR knockout with ChIP and rescue in pro-B cells; ChIP-PCR with zebrafish loss-of-function for prdm16; AR ChIP-seq with paracrine co-culture\",\n      \"pmids\": [\"34382935\", \"34330825\", \"33503448\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether these targets are bound as part of the canonical pentameric complex not always defined\", \"Single-lab studies awaiting independent confirmation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How LMO2's distinct activities—nuclear transcriptional scaffolding, replication-origin licensing, 53BP1-mediated repair inhibition, and cytoplasmic cofilin/DVL interactions—are partitioned and regulated within a single cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model coordinating nuclear-transcriptional, replication, repair, and cytoplasmic functions\", \"Signals controlling nuclear versus cytoplasmic localization not defined\", \"Acetyltransferase opposing SIRT2 and full degradation machinery for free LMO2 unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 6, 9]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 3, 14]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [33]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [33, 34]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 9, 29]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 5, 8]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [13, 22, 16]}\n    ],\n    \"complexes\": [\n      \"TAL1/SCL-E47-GATA1-LDB1 pentameric complex\",\n      \"LMO2-LDB1 complex\",\n      \"LMO2-SAP18-HDAC1 repressor complex\"\n    ],\n    \"partners\": [\n      \"TAL1\",\n      \"LDB1\",\n      \"GATA1\",\n      \"E47\",\n      \"LYL1\",\n      \"53BP1\",\n      \"POLD1\",\n      \"DVL1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}